Personalized Antisense Oligonucleotide for A Single Participant With GARS1 Gene Mutation Associated With Charcot-Marie-Tooth Disease Type 2D (CMT2D)
Clinical trial NCT07226297 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07226297
- Sponsor
- n-Lorem Foundation
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-27
- Primary completion
- 2027-10-01
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.